Everolimus

Nature Reviews Drug Discovery

Volumn 8, Issue 7, 2009, Pages 535-536

  Atkins, Michael B ^a   Yasothan, Uma ^b   Kirkpatrick, Peter ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*

Author keywords

[No Author keywords available]

Indexed keywords

AFINITOR; ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; FK 506 BINDING PROTEIN; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG STRUCTURE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; SURVIVAL TIME;

CARCINOMA, RENAL CELL; DRUG DISCOVERY; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67650088409     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2924     Document Type: Article

References (13)

1. Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477-2490 (2005).
2. Garcia, J. A. & Rini, B. I. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J. Clin. 57, 112-125 (2007).
3. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 1 Jun 2009 (doi: 10.1200/ JCO.2008.20.1293).
4. Faivre, S., Kroemer, G. & Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nature Rev. Drug Discov. 5, 671-688 (2006).
5. Rini, B, Kar, S. & Kirkpatrick, P. Temsirolimus. Nature Rev. Drug Discov. 6, 599-600 (2007).
6. Schuler, W. et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64, 36-42 (1997).
7. Sedrani, R. et al. Chemical modification of rapamycin: The discovery of SDZ RAD. Transplant Proc. 30, 2192-2194 (1998).
8. Food and Drug Administration. FDA labelling information. FDA web site [online], http://www.accessdata.fda.gov/drugsatfda_docs/ label/2009/022334lbl.pdf (2009).
9. Lane, H. A. et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin. Cancer Res. 15, 1612-1622 (2009).
10. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
11. Atkins, M. B. et al. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer 115, S2247-S2251 (2009).
12. IMS MIDAS (2008).
13. Hauber, A. et al. JP Morgan European Equity Research Report (JP Morgan Chase and Company, 29 Jan 2009).